David Brown's Email Addresses & Phone Numbers

Dr David Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche; and also as President and Chief Executive of Cellzome AG, a biotechnology company with headquarters in Heidelberg, Germany. Whilst at...

Dr David Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche; and also as President and Chief Executive of Cellzome AG, a biotechnology company with headquarters in Heidelberg, Germany. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team that invented and developed Viagra through to proof of clinical efficacy in male impotence. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have achieved sales of over $30 billion. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia. Dr Brown has a strong interest in entrepreneurialism. He coaches CEOs and entrepreneurs at the Centre for Entrepreneurial Learning at Cambridge University Business School and he is an Angel Investor in high-technology start-up companies. He co-founded Crescendo Biologics of which he is currently interim Chair of the board. He also serves on the boards of Amura Ltd (Chair), ProFactor Pharma Ltd (Chair) and Babraham Institute Enterprise Ltd (Chair). He serves on the Technology Transfer Strategy Panel of the Wellcome Trust, London, which provides governance oversight and guidance on strategic direction for the Trust's grant-awarding bodies. He is a Trustee of two charities, Antibiotic Research UK, dedicated to solving the looming problem of antibiotic resistance; and Friends of Manjushree Vidyapith School and Orphanage, a charity he co-founded in 2005 to help destitute orphans in South Tibet.Trustee (Director); and member of the Science and Technology Advisory Committee. @ The world's first charity dedicated to helping solve the antibiotic resistance problem. The research programmes will be undertaken in the UK’s universities, institutes and specialty pharmaceutical companies and will focus for the next few years on finding drugs which are ‘antibiotic resistance breakers’ (ARBs). ARBs might be (non-antibiotic) drugs used to treat other medical conditions which when given together with an existing antibiotic overcome the resistance. From October 2014 to Present (1 year 3 months) Chair of the Board of Directors @ BIE commercializes research from the Babraham Institute From September 2014 to Present (1 year 4 months) Chairman of the Board of Directors @ ProFactor Pharma Ltd (PFP) was established to commercialise and supply recombinant blood factors for the treatment of haemophilia to a severely under-supplied world market. Its objective is to make more product available to treat more patients. PFP has developed cell lines expressing FVIII using GMP qualified Chinese Hamster Ovary cells. These will be used in low cost disposable production technologies in a production process capable of replication anywhere in the world. Modern downstream purification technologies give a high yield of final product. From September 2013 to Present (2 years 4 months) Interim Chair of the Board of Directors @ Cofounder of Crescendo Biologics, which develops fully human VH fragment antibodies. Crescendo was formed in December 2008 with funding from four investors: Sofinnova Partners, Aitua, Avlar BioVentures, and Rainbow Seed Fund. The company was established from technology developed at the Babraham Institute and is based at Babraham Research Campus, Cambridge, UK From December 2008 to Present (7 years 1 month) Chairman of the Board @ www.fmvso.org FMVSO is a registered UK charity providing support for orphans, handicapped and destitute Tibetan children in the high Himalayas of NE India. In September 2005, a small group from UK travelled to the ‘Land of the Dawn-Lit Mountains’ – the state of Arunachal Pradesh in the Himalayas of North-East India. Once part of Tibet, this region is closer to Lhasa than it is to any big town in India. The travellers witnessed first-hand the poverty and deprivation and the struggle for survival of the people, principally of the Monpa tribe, who are more Tibetan than Indian in their culture and traditions. When visiting Manjushree Vidyapith School and Orphanage near the small town of Tawang they were deeply moved by what they found there, They decided they should do what they could to help, and pledged their support to Lama Thupten Phuntsok, the founder and principal. FMVSO now provides much of the food for the orphanage and supports education costs for over 200 children. Trustees of the charity visit the orphanage every year and work there for several weeks helping the children and teachers. From March 2006 to Present (9 years 10 months) Chair of Science Advisory Board @ Developing global strategy and drug projects to reduce the 2 million child deaths annually from diarrheal diseases in developing countries. Devised a drug treatement for cholera and E coli infections that will commence clinical trials in Bangladesh in 2014. This could be the first example of an anti-infective that will not drive development of drug resistance. Linked to network of global key opinion leaders in diarrheal diseases. From February 2005 to Present (10 years 11 months) Chairman @ Amura has a number of drugs ready for entry to IND studies for treatment of pain, osteoporosis osteoarthritis, rheumatoid arthritis and cancer metastasis. From 2005 to Present (10 years) Managing Director @ Founder of this privately held consultancy practice, which provides consultancy services to pharmaceutical and biotechnology companies and to the venture capital industry From 2005 to Present (10 years) Chair of the Board of Directors @ Indigix is developing a first-in-class drug called INX201, which is a breakthrough in the treatment of severe bacterial infections. Initially INX201 is being developed for treatment of gut-borne diarrhea diseases but it also has significant potential for infections in other body compartments. INX201 will be the first-ever drug based on the novel concept of protecting the host instead of killing bacteria. This breakthrough could be as significant as the discovery of the first antibiotics or vaccines. Importantly, bacterial resistance to INX201 cannot emerge because the target is a host cell surface receptor. It will play a leading role in solving the antibiotic resistance problem. INX201 will lead a whole new generation of anti-infective agents not susceptible to bacterial resistance. It will prove, for the first time, a ‘third paradigm’ for managing bacterial diseases alongside vaccines and antibiotics, and open up drug discovery for a new class of pharmaceuticals. INX201's antibiotic sparing effect will lead to substantial healthcare related cost savings, and save many lives globally. From 2011 to January 2015 (4 years) Chairman of the board of directors @ Babraham Commercialisation Services Limited (BCS) is the wholly-owned trading arm of the Babraham Institute. The Babraham Institute undertakes innovative life-sciences research to discover the molecular mechanisms that underlie normal cellular processes and functions, with the aim of improving lifelong wellbeing and healthy ageing. It is based on the Babraham Research Campus near Cambridge, which is also home to early-stage biomedical companies. BCS is responsible for commercialisation of the Babraham Institute's science. It manages, develops and commercialises the Babraham Institute's intellectual property portfolio. It also facilitates collaborations between the Institute and industry, and arranges access to the Institute's expertise and scientific facilities and services. Crescendo Biologics was a spin-out from Babraham Institute. From September 2012 to September 2014 (2 years 1 month) Chairman @ BBT is the commercial arm of Babraham Research Campus. It manages the facilities for the 32 biotechnology companies based on the park. It also establishes new biotechnology companies based on the IP generated on the campus by the Babraham Institute, which houses over 400 world-class scientists engaged in epigenetics and cell signalling research, funded by the UK government body, the BBSRC. From 2006 to August 2013 (7 years) Chief Executive Officer @ Biotechnology company based in Heidelberg, Germany and Cambridge, UK. Sold to GSK in 2012. From 2002 to 2004 (2 years) Research Director @ Global Head of Drug Discovery. Director of the company and responsible for productivity of over 2000 staff focused on drug discovery at all six of Roche's research sites in the USA, Europe and Asia. He also served on Clinical Development and Business Development senior committees. From 1999 to 2002 (3 years) Head of Medicinal Sciences Division @ From 1995 to 1999 (4 years) Department Head, Medicinal Chemistry @ Instrumental in discovery of 3 drugs that to date have earned Pfizer over $30 billion in sales (Viagra for male erectile dysfunction, Revatio for pulmonary hypertension, Relpax for migraine). Led team that discovered Viagra for 8 years, from start-up of the research to the discovery of effects in male impotence patients. Named co-inventor on the patent. From 1985 to 1995 (10 years) Medicinal Chemist @ From 1974 to 1985 (11 years) PhD, Chemistry @ University of Bristol From 1971 to 1974 Bachelor of Science (BSc), 1st Class Honours @ University of East Anglia From 1968 to 1971 David Brown is skilled in: Drug Discovery, Biotechnology, Technology Transfer, Biopharmaceuticals, Biochemistry, Medicinal Chemistry, Board of Director experience, Strategic Leadership, Pharmaceutical Industry, Lifesciences, IND, Venture Capital, Board of Directors, Pharmaceutics, Neuroscience